Neutralizing Antibody Activity Against the B.1.617.2 (delta) Variant Before and After a Third BNT162b2 Vaccine Dose in Hemodialysis Patients

Neutralizing Antibody Activity Against the B.1.617.2 (delta) Variant Before and After a Third BNT162b2 Vaccine Dose in Hemodialysis Patients

Hemodialysis patients are at high risk for severe COVID-19, and impaired seroconversion rates have been demonstrated after COVID-19 vaccination. Humoral immunity wanes over time and variants of concern with immune escape are posing an increasing threat. Little is known about protection against the B...

Full description

Bibliographic Details
Main Authors: Louise Benning, Katrin Klein, Christian Morath, Marie Bartenschlager, Heeyoung Kim, Mirabel Buylaert, Marvin Reineke, Maximilian Töllner, Christian Nusshag, Florian Kälble, Paula Reichel, Paul Schnitzler, Martin Zeier, Caner Süsal, Ralf Bartenschlager, Matthias Schaier, Claudius Speer
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-03-01
Series:Frontiers in Immunology
Subjects:
SARS-CoV-2
COVID-19
hemodialysis
variants of concern
delta variant
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.840136/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.840136/full

Similar Items